Ulefnersen

RNA / oligonucleotide

Reliablesignal

Evidence outlook · lead readout

FUS-ALS (NCT04768972) · Amyotrophic Lateral Sclerosis

The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.

FUS-ALS (NCT04768972): This trial randomized 89 participants with FUS-ALS to double-blind ulefnersen or placebo, comparing them on a composite clinical measure of functional decline, need for rescue treatment, and survival free of permanent ventilation -- a hard, disease-defining outcome rather than a lab biomarker. According to results reported outside the registry, the treatment arm showed a statistically significant benefit over placebo on this primary comparison (p=0.0005), which together with the randomized, blinded, placebo-controlled design supports a strong evidence rating.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Amyotrophic Lateral Sclerosis

Competitive landscape

This drug's own stage for Amyotrophic Lateral Sclerosis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ulefnersen: this drugPhase 3RNA / oligonucleotideFUSReliable signal
NCT04768972: FUSION (NCT04768972): ulefnersen met its primary endpoint, a joint rank (win-ratio style) analysis of time to death/permanent ventilation, time to rescue, and change in ALSFRS-R score to Day 505 vs placebo; p=0.0005.
Edaravone (Radicava ORS)ApprovedSmall moleculeReactive oxygen species (ROS)Weak signalFeatured results are safety only in this race
Tofersen (Qalsody)ApprovedRNA / oligonucleotideSOD1Partial signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication
CB03-154Phase 2/3Small moleculeKCNQ2/3 (Kv7.2/7.3) potassium channel (opener)not yet gradedNo reviewed efficacy summary in this indication
CNM-Au8Phase 2/3Nanoparticlemitochondrial energy metabolismnot yet gradedNo reviewed efficacy summary in this indication
IbudilastPhase 2/3Small moleculePDE4 and PDE10; macrophage migration inhibitory factor (MIF)not yet gradedNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2/3Small moleculeDendritic spine densityWeak signalFeatured results are safety only in this race
DazucorilantPhase 2Small moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
ForalumabPhase 2Monoclonal antibodyCD3not yet gradedNo reviewed efficacy summary in this indication
ALN-SODPhase 1/2RNA / oligonucleotideSOD1not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 September 2026Topline resultFUSION Phase 3 meets primary endpoint
Ionis Pharmaceuticals · Source ↗